1059705-07-5Relevant academic research and scientific papers
TETRAHYDROPYRAN-BASED THIODISACCHARIDE MIMICS AS GALECTIN-3 INHIBITORS
-
Page/Page column 22, (2020/01/08)
The present disclosure relates to compounds of Formula (1), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods making and using such compounds and compositions.
Synthesis and Structural Characterization of Ethynylene-Bridged Bisazines Featuring Various α-Substitution
Hübscher, J?rg,Seichter, Wilhelm,Gruber, Thomas,Kortus, Jens,Weber, Edwin
, p. 1062 - 1074 (2015/08/06)
A series of bispyridines and bispyrimidines 1a, 1b, 1c, 1d, 1e showing the heterocycles attached to both ends of an ethynylene unit and being α-substituted with chloro, tert-butylthio, and methoxy groups have been synthesized via cross-coupling technique and their crystal structures studied by X-ray diffraction analysis. Supramolecular interactions of C-H···N and π···π stacking type were found to largely dominate the structures according to the compound species. A trial was given to deduce the markedly differing temperatures of melting among the compounds from special features of the crystal structures.
HETEROCYCLIC COMPOUNDS AND USES THEREOF
-
Paragraph 00653; 00654; 00659, (2015/04/22)
Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF PI3K-GAMMA MEDIATED DISORDERS
-
Paragraph 001310, (2015/11/10)
Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER
-
, (2008/12/07)
A CPT inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
